Loading clinical trials...
Loading clinical trials...
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Immunogenicity, and Preliminary Anti-tumor Activity of SYS6005 in Patients With Advanced Malignant Tumor
Conditions
Interventions
SYS6005
Locations
1
China
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Tianjin, China
Start Date
April 3, 2025
Primary Completion Date
January 30, 2027
Completion Date
June 30, 2028
Last Updated
May 14, 2025
NCT06898450
NCT06658951
NCT05101070
NCT05719558
NCT06716138
NCT06307795
Lead Sponsor
CSPC Megalith Biopharmaceutical Co.,Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions